Hivis

Hivis is an oral medication whose active ingredient is diosmin, a flavonoid commonly used in venous disease management. Marketed in the European Union, Hivis is supplied as an oral dosage form, though the exact strength is not disclosed on the label. As a phlebotonic agent, it belongs to the therapeutic class of venous disease treatments and is classified under ATC code C05CA03 and is intended for adult patients.

Hivis is indicated for conditions related to impaired venous return and capillary fragility.

- Chronic venous insufficiency (CVI) presenting with leg heaviness, swelling, or varicose veins. - Hemorrhoidal disease, including symptomatic internal or external hemorrhoids. - Post‑thrombotic syndrome where venous circulation remains compromised after deep‑vein thrombosis. - Venous stasis dermatitis characterized by skin changes due to poor venous drainage. - Mild peripheral edema associated with venous disorders.

Adverse reactions reported with diosmin-containing products are generally mild, but rare serious events have been described.

Common: - Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia. - Headache or mild dizziness. - Skin flushing or mild pruritus. - Transient increase in urinary frequency.

Serious: - Allergic reactions including rash, urticaria, or angioedema. - Hepatic enzyme elevation or liver dysfunction.

When considering Hivis, clinicians should evaluate patient-specific factors and potential contraindications.

- Use with caution in patients with known hypersensitivity to diosmin or related flavonoids. - Assess liver function before initiating therapy, especially in individuals with pre‑existing hepatic disease. - Monitor for bleeding tendencies if combined with anticoagulants or antiplatelet agents. - Avoid use during pregnancy or lactation unless the benefit outweighs potential risk, as safety data are limited. - Consider renal impairment; dose adjustment may be required in severe cases. - Review concomitant use of other venotonic or phytotherapeutic products to prevent additive effects.

Diosmin may interact with certain medications, influencing efficacy or safety.

Avoid: - Concurrent use with potent anticoagulants (e.g., warfarin, direct oral anticoagulants) due to increased bleeding risk. - Combination with high‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that also affect platelet function.

Use with caution: - Co‑administration with other phlebotonic agents or herbal extracts (e.g., hesperidin, rutin) may potentiate venous effects. - Use alongside diuretics, as fluid balance changes could modify therapeutic response. - Patients on antihypertensive drugs should be monitored for additive blood‑pressure lowering effects.